These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Blood platelets metabolic and activation processes and options for their inhibition]. Pecka M; Malý J Vnitr Lek; 2009 Mar; 55(3):263-6. PubMed ID: 19378857 [TBL] [Abstract][Full Text] [Related]
3. Isomers of trans fatty acids modify the activity of platelet 12-P lipoxygenase and cyclooxygenase/thromboxane synthase. Stachowska E; Dołegowska B; Olszewska M; Gutowska I; Chlubek D Nutrition; 2004 Jun; 20(6):570-1. PubMed ID: 15165621 [TBL] [Abstract][Full Text] [Related]
4. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. Rotondo S; Krauze-Brzósko K; Manarini S; Evangelista V; Cerletti C Eur J Pharmacol; 2004 Mar; 488(1-3):79-83. PubMed ID: 15044038 [TBL] [Abstract][Full Text] [Related]
5. [The effect of the new Russian concentrate of n-3 polyunsaturated fatty acids epaden on thrombocyte functional activity in vitro]. Kalugin SA; Petrukhina GN; Makarov VA; Gandel' VG Eksp Klin Farmakol; 2000; 63(1):45-50. PubMed ID: 10763110 [TBL] [Abstract][Full Text] [Related]
7. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions. Bilodeau ML; Hamm HE J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299 [TBL] [Abstract][Full Text] [Related]
8. Platelet activation induces cell-surface immunoreactive tissue factor expression, which is modulated differently by antiplatelet drugs. Camera M; Frigerio M; Toschi V; Brambilla M; Rossi F; Cottell DC; Maderna P; Parolari A; Bonzi R; De Vincenti O; Tremoli E Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1690-6. PubMed ID: 12855480 [TBL] [Abstract][Full Text] [Related]
9. Amifostine, a reactive oxigen species scavenger with radiation- and chemo-protective properties, inhibits in vitro platelet activation induced by ADP, collagen or PAF. Porta C; Maiolo A; Tua A; Grignani G Haematologica; 2000 Aug; 85(8):820-5. PubMed ID: 10942928 [TBL] [Abstract][Full Text] [Related]
10. Activation of human platelets by misfolded proteins. Herczenik E; Bouma B; Korporaal SJ; Strangi R; Zeng Q; Gros P; Van Eck M; Van Berkel TJ; Gebbink MF; Akkerman JW Arterioscler Thromb Vasc Biol; 2007 Jul; 27(7):1657-65. PubMed ID: 17510465 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of GBH on platelet aggregation through inhibition of intracellular Ca2+ mobilization in activated human platelets. Park WH; Kim HK; Nam KS; Shon YH; Jeon BH; Moon SK; Kim MG; Kim CH Life Sci; 2004 Nov; 75(25):3063-76. PubMed ID: 15474558 [TBL] [Abstract][Full Text] [Related]
12. Adenosine diphosphate receptors on blood platelets: potential new targets for antiplatelet therapy. Rozalski M; Nocun M; Watala C Acta Biochim Pol; 2005; 52(2):411-5. PubMed ID: 15912207 [TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482 [TBL] [Abstract][Full Text] [Related]
14. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Cattaneo M Eur Heart J; 2007 Jul; 28(14):1673-5. PubMed ID: 17586540 [No Abstract] [Full Text] [Related]
15. 2-(2-Br-phenyl)-8-methoxy-benzoxazinone (HPW-RX2), a direct thrombin inhibitor with a suppressive effect on thromboxane formation in platelets. Wu CC; Wang TW; Wang WY; Hsieh PW; Wu YC Eur J Pharmacol; 2005 Dec; 527(1-3):37-43. PubMed ID: 16313903 [TBL] [Abstract][Full Text] [Related]
16. Thiosulfinates modulate platelet activation by reaction with surface free sulfhydryls and internal thiol-containing proteins. Badol P; David-Dufilho M; Auger J; Whiteheart SW; Rendu F Platelets; 2007 Nov; 18(7):481-90. PubMed ID: 17852771 [TBL] [Abstract][Full Text] [Related]
17. Nitridergic platelet pathway activation by hementerin, a metalloprotease from the leech Haementeria depressa. Chudzinski-Tavassi AM; Bermej E; Rosenstein RE; Faria F; Sarmiento MI; Alberto F; Sampaio MU; Lazzari MA Biol Chem; 2003 Sep; 384(9):1333-9. PubMed ID: 14515997 [TBL] [Abstract][Full Text] [Related]
18. Control of platelet activation by cyclic AMP turnover and cyclic nucleotide phosphodiesterase type-3. Feijge MA; Ansink K; Vanschoonbeek K; Heemskerk JW Biochem Pharmacol; 2004 Apr; 67(8):1559-67. PubMed ID: 15041473 [TBL] [Abstract][Full Text] [Related]
19. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro. Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514 [TBL] [Abstract][Full Text] [Related]
20. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]